Related references
Note: Only part of the references are listed.A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette et al.
HORMONE AND METABOLIC RESEARCH (2019)
High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation
Joaquim Carreras et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY (2019)
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
Emma S. Scott et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Current and future immunotherapies for thyroid cancer
Alessandro Antonelli et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Vasculitis associated with immune checkpoint inhibitors-a systematic review
Anisha Daxini et al.
CLINICAL RHEUMATOLOGY (2018)
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki Stamatouli et al.
DIABETES (2018)
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
Francois-Xavier Danlos et al.
EUROPEAN JOURNAL OF CANCER (2018)
Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer
Sonja Badovinac et al.
IMMUNOTHERAPY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician
Eric D. Hansen et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Regulatory mechanisms of PD-L1 expression in cancer cells
Yongyu Shi
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Thyroid disorders induced by checkpoint inhibitors
Silvia Martina Ferrari et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2018)
Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
Rachel Ryu et al.
FRONTIERS IN ONCOLOGY (2018)
Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment
Pauline Campredon et al.
EUROPEAN THYROID JOURNAL (2018)
Review of checkpoint immunotherapy for the management of non-small cell lung cancer
Shine Raju et al.
IMMUNOTARGETS AND THERAPY (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Endocrine side effects of cancer immunotherapy
Priscilla Cukier et al.
ENDOCRINE-RELATED CANCER (2017)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient
Manuel Araujo et al.
IMMUNOTHERAPY (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies
David J. Byun et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
James Luke Godwin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management
Jonathan Kapke et al.
CASE REPORTS IN ONCOLOGY (2017)
Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review
Marie-Lea Gauci et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Mario Sznol et al.
CANCER TREATMENT REVIEWS (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat et al.
ANNALS OF ONCOLOGY (2016)
Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
Tomohiko Narita et al.
JOURNAL OF DERMATOLOGY (2016)
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Alexander Faje
PITUITARY (2016)
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
Gregory T. Wurz et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Daphne Day et al.
BIODRUGS (2016)
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
Thomas K. Eigentler et al.
CANCER TREATMENT REVIEWS (2016)
Management of toxicities of immune checkpoint inhibitors
Lavinia Spain et al.
CANCER TREATMENT REVIEWS (2016)
Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review
M. N. Joshi et al.
CLINICAL ENDOCRINOLOGY (2016)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
FUTURE ONCOLOGY (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Anti-PD-L1 inhibitor durvalumab in bladder cancer
Vicki Brower
LANCET ONCOLOGY (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Jeffrey S. Weber et al.
ONCOLOGIST (2016)
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
Elisa Gonzalez-Rodriguez et al.
ONCOLOGIST (2016)
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
Jared R. Lowe et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Noha Abdel-Wahab et al.
PLOS ONE (2016)
Hyponatraemia secondary to nivolumab-induced primary adrenal failure
Harris Trainer et al.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS (2016)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
Juan Martin-Liberal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Ipilimumab-Induced Adrenalitis A Possible Pitfall in 18F-FDG-PET/CT
Sara Bacanovic et al.
CLINICAL NUCLEAR MEDICINE (2015)
Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
Mahnaz Mellati et al.
DIABETES CARE (2015)
Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
Caroline Gaudy et al.
DIABETES CARE (2015)
Nivolumab in combination with ipilimumab for the treatment of melanoma
Rajasekharan Somasundaram et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
Steven Orlov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience
J. Gao et al.
ONCOGENE (2015)
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naive Patients with Metastatic Uveal Melanoma
Lisa Zimmer et al.
PLOS ONE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Ipilimumab-induced hypophysitis: review of the literature
P. B. Araujo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2015)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
Le Min et al.
CLINICAL CANCER RESEARCH (2015)
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival
Alessandra De Remigis et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma
Michele Del Vecchio et al.
EUROPEAN JOURNAL OF CANCER (2014)
Pidilizumab in the treatment of diffuse large B-cell lymphoma
Locke J. Bryan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Immune Checkpoint Blockade
Jarushka Naidoo et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
What have we learned from cancer immunotherapy in the last 3 years?
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
Paolo A. Ascierto et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports
Joke Marlier et al.
ENDOCRINE (2014)
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)
Sander Kelderman et al.
ACTA ONCOLOGICA (2013)
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
M. Maio et al.
ANNALS OF ONCOLOGY (2013)
Clinical Activity of Ipilimumab for Metastatic Uveal Melanoma
Jason J. Luke et al.
CANCER (2013)
mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
Francesco Torino et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Salvatore Maria Corsello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Ipilimumab for Patients With Advanced Mucosal Melanoma
Michael A. Postow et al.
ONCOLOGIST (2013)
Ipilimumab-induced autoimmune adrenalitis
Le Min et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Fall in C-Peptide During First 2 Years From Diagnosis Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes Trial Net Data
Carla J. Greenbaum et al.
DIABETES (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons J. M. van den Eertwegh et al.
LANCET ONCOLOGY (2012)
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Ravi A. Madan et al.
LANCET ONCOLOGY (2012)
Autoimmunity associated with immunotherapy of cancer
Sally M. Amos et al.
BLOOD (2011)
Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10
Alessandro Antonelli et al.
CYTOKINE (2011)
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Le Min et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Clinical Applications of Diabetes Antibody Testing
Polly J. Bingley
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Troy Dillard et al.
PITUITARY (2010)
Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab
Antoni Ribas
SEMINARS IN ONCOLOGY (2010)
Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2009)
Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells
Alessandro Antonelli et al.
CLINICAL ENDOCRINOLOGY (2009)
Dysregulation of secretion of CXC α-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-γ agonists
Alessandro Antonelli et al.
ENDOCRINE-RELATED CANCER (2009)
High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma
Joaquim Carreras et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Immunotherapy of autoimmunity and cancer: the penalty for success
Rachel R. Caspi
NATURE REVIEWS IMMUNOLOGY (2008)
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
Joaquim Carreras et al.
BLOOD (2006)
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
AV Maker et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
JA Blansfield et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Autoimmune hypophysitis
P Caturegli et al.
ENDOCRINE REVIEWS (2005)
Share Paper
